Location of functioning metastases from differentiated thyroid carcinoma by simultaneous double isotope acquisition of I-131 whole body scan and bone scan

Ceccarelli, Claudia; Bianchi, Francesca; Trippi, D; Brozzi, Federica; Martino, Federica; Santini, Pierina; Elisei, Rossella; Pinchera, Aldo

doi:10.1007/bf03346282

Cited by 7 publications

(6 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multi-isotope SPECT or SPECT/PET imaging techniques have certainly previously been utilised in angiogenesis [12], brain [13], cardiac [14], infection [15,16], and thrombus [17] imaging investigations, including in the clinic. The most common radioisotope combinations used in these studies are 111 In/ 99m Tc [18], 123 I/ 99m Tc [13], 131 I/ 99m Tc [19], 201 Tl/ 99m Tc [20], 111 In/ 177 Lu [12], and 125 I/ 111 In/ 68 Ga [17]. The combination of radioisotopes used here 111 In/ 89 Zr, is remarkably well-suited to dual-isotope imaging as the principle γ-emissions resulting from the decay of 89 Zr at 511 keV ( β + / β − annihilation) and 909 keV are easily resolved from the lower energy γ-emissions of 111 In (171 and 245 keV), resulting in minimal spectral overlap and crosstalk effects.…”

Section: Introductionmentioning

confidence: 99%

Dual-isotope imaging allows in vivo immunohistochemistry using radiolabelled antibodies in tumours

Knight

Mosley

Kersemans

et al. 2019

Nuclear Medicine and Biology

View full text Add to dashboard Cite

While radiolabelled antibodies have found great utility as PET and SPECT imaging agents in oncological investigations, a notable shortcoming of these agents is their propensity to accumulate non-specifically within tumour tissue. The degree of this non-specific contribution to overall tumour uptake is highly variable and can ultimately lead to false conclusions. Therefore, in an effort to obtain a reliable measure of inter-individual differences in non-specific tumour uptake of radiolabelled antibodies, we demonstrate that the use of dual-isotope imaging overcomes this issue, enables true quantification of epitope expression levels, and allows non-invasive in vivo immunohistochemistry. The approach involves co-administration of (i) an antigen-targeting antibody labelled with zirconium-89 ( 89 Zr), and (ii) an isotype-matched non-specific control IgG antibody labelled with indium-111 ( 111 In). As an example, the anti-HER2 antibody trastuzumab was radiolabelled with 89 Zr, and co-administered intravenously together with its 111 In-labelled non-specific counterpart to mice bearing human breast cancer xenografts with differing HER2 expression levels (MDA-MB-468 [HER2-negative], MDA-MB-231 [low-HER2], MDA-MB-231/H2N [medium-HER2], and SKBR3 [high-HER2]). Simultaneous PET/SPECT imaging using a MILabs Vector4 small animal scanner revealed stark differences in the intratumoural distribution of [ 89 Zr]Zr-trastuzumab and [ 111 In]In-IgG, highlighting regions of HER2-mediated uptake and non-specific uptake, respectively. Normalisation of the tumour uptake values and tumour-to-blood ratios obtained with [ 89 Zr]Zr-trastuzumab against those obtained with [ 111 In]In-IgG yielded values which were most strongly correlated (R = 0.94; P = 0.02) with HER2 expression levels for each breast cancer type determined by Western blot and in vitro saturation binding assays, but not non-normalised uptake values. Normalised intratumoural distribution of [ 89 Zr]Zr-trastuzumab correlated well with intratumoural heterogeneity HER2 expression.

show abstract

Section: Introductionmentioning

confidence: 99%

Dual-isotope imaging allows in vivo immunohistochemistry using radiolabelled antibodies in tumours

Knight

Mosley

Kersemans

et al. 2019

Nuclear Medicine and Biology

View full text Add to dashboard Cite

show abstract

“…Not only is imaging feasible with commercial SPECT cameras, but ongoing technology, such as Compton cameras also provide an avenue for imaging options of higher energy gammas [ 17 ]. It is noted that whole body, simultaneous dual isotopic imaging of 99m Tc and 131 I has been reported for the use of locating functioning bone metastases arising from residual differentiated thyroid carcinoma (DTC) following 131 I thyroid ablation [ 88 , 89 ].…”

Section: Discussionmentioning

confidence: 99%

Fusion-Based Neutron Generator Production of Tc-99m and Tc-101: A Prospective Avenue to Technetium Theranostics

Mausolf¹,

Johnstone²,

Mayordomo

et al. 2021

Pharmaceuticals

View full text Add to dashboard Cite

Presented are the results of 99mTc and 101Tc production via neutron irradiation of natural isotopic molybdenum (Mo) with epithermal/resonance neutrons. Neutrons were produced using a deuterium-deuterium (D-D) neutron generator with an output of 2 × 1010 n/s. The separation of Tc from an irradiated source of bulk, low-specific activity (LSA) Mo on activated carbon (AC) was demonstrated. The yields of 99mTc and 101Tc, together with their potential use in medical single-photon emission computed tomography (SPECT) procedures, have been evaluated from the perspective of commercial production, with a patient dose consisting of 740 MBq (20 mCi) of 99mTc. The number of neutron generators to meet the annual 40,000,000 world-wide procedures is estimated for each imaging modality: 99mTc versus 101Tc, D-D versus deuterium-tritium (D-T) neutron generator system outputs, and whether or not natural molybdenum or enriched targets are used for production. The financial implications for neutron generator production of these isotopes is also presented. The use of 101Tc as a diagnostic, therapeutic, and/or theranostic isotope for use in medical applications is proposed and compared to known commercial nuclear diagnostic and therapeutic isotopes.

show abstract

“…paired-agent framework, provided sensitivity challenges can be overcome [19,20]. Studies using dual-isotope PET/SPECT demonstrate a potential path towards quantifying RA using a cross-modality PAI framework [21,[36][37][38].…”

Section: Discussionmentioning

confidence: 99%

Examining the Feasibility of Quantifying Receptor Availability Using Cross-Modality Paired-Agent Imaging

Meng

Sadeghipour²,

Folaron

et al. 2021

Mol Imaging Biol

View full text Add to dashboard Cite

Purpose The ability to noninvasively quantify receptor availability (RA) in solid tumors is an aspirational goal of molecular imaging, often challenged by the influence of non-specific accumulation of the contrast agent. Paired-agent imaging (PAI) techniques aim to compensate for this effect by imaging the kinetics of a targeted agent and an untargeted isotype, often simultaneously, and comparing the kinetics of the two agents to estimate RA. This is usually accomplished using two spectrally distinct fluorescent agents, limiting the technique to superficial tissues and/or preclinical applications. Applying the approach in humans using conventional imaging modalities is generally infeasible since most modalities are unable to routinely image multiple agents simultaneously. We examine the ability of PAI to be implemented in a cross-modality paradigm, in which the targeted and untargeted agent kinetics are imaged with different modalities and used to recover receptor availability. Procedures Eighteen mice bearing orthotopic brain tumors were administered a solution containing three contrast agents: (1) a fluorescent agent targeted to epidermal growth factor receptor (EGFR), (2) an untargeted fluorescent isotype, and (3) a gadolinium-based contrast agent (GBCA) for MRI imaging. The kinetics of all three agents were imaged for 1 h after administration using an MRI-coupled fluorescence tomography system. Paired-agent receptor availability was computed using (1) the conventional all-optical approach using the targeted and untargeted optical agent images and (2) the cross-modality approach using the targeted optical and untargeted MRI-GBCA images. Receptor availability estimates between the two methods were compared. Results Receptor availability values using the cross-modality approach were highly correlated to the conventional, single-modality approach (r = 0.94; p < 0.00001). Conclusion These results suggest that cross-modality paired-agent imaging for quantifying receptor availability is feasible. Ultimately, cross-modality paired-agent imaging could facilitate rapid, noninvasive receptor availability quantification in humans using hybrid clinical imaging modalities.

show abstract

Location of functioning metastases from differentiated thyroid carcinoma by simultaneous double isotope acquisition of I-131 whole body scan and bone scan

Cited by 7 publications

References 10 publications

Dual-isotope imaging allows in vivo immunohistochemistry using radiolabelled antibodies in tumours

Dual-isotope imaging allows in vivo immunohistochemistry using radiolabelled antibodies in tumours

Fusion-Based Neutron Generator Production of Tc-99m and Tc-101: A Prospective Avenue to Technetium Theranostics

Examining the Feasibility of Quantifying Receptor Availability Using Cross-Modality Paired-Agent Imaging

Contact Info

Product

Resources

About